Therapy innovations: tyrosine kinase inhibitorsfor the treatment of pancreatic neuroendocrine tumors
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Eric Raymond & Timothy Hobday & Daniel Castellano &Diane Reidy-Lagunes & Rocیo Garcیa-Carbonero & Alfredo Carrato
- چاپ و سال / کشور: 2011
Description
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEPNETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulinlike growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.
Cancer Metastasis Rev (2011) 30 (Suppl 1):S19–S26 DOI 10.1007/s10555-011-9291-2 Published online: 10 February 2011
